Even people who took one, two, or three experimental coronavirus “vaccine” shots during the height of the coronavirus scare are saying “nope” to taking any more “boosters.” Yet, behind the scenes, the United States government has kept funding companies in the pharmaceutical industry to continue developing new iterations of the unpopular “vaccines.”
This situation may be changing. A new action by US Health and Human Services Secretary Robert F. Kennedy, Jr. puts a temporary halt to US support for the development of a pill form of coronavirus “vaccine.” This could be the start of an exit of the US altogether from aiding coronavirus “vaccine” development and, possibly, from aiding other drug development as well.
Emma Colton provided in a Tuesday Fox News article details regarding how Kennedy “issued a 90-day stop-work order on Friday related to the HHS contract with American biotech company Vaxart Inc., which is working to develop a new COVID-19 vaccine that can be taken orally.” “Kennedy and other health officials,” further wrote Colton, are “set to examine the study’s initial findings over the next 90 days before deciding on next steps.” This pause, Colton notes, prevents Vaxart from invoicing of the US government for 230 million dollars for clinical trials.
The US government has been a key participant in the experimental coronavirus shots push. President Donald Trump helped ramp it up with the creation of Operation Warp Speed to develop coronavirus shots and then inject them quickly into as many people as possible. President Joe Biden and politicians on the state and local level also sought to increase “demand” for the shots by imposing mandates that people take them in order to keep their jobs, enter stores and other locations, or otherwise proceed with their ordinary activities. Kennedy’s initiation of a pause in Vaxart support, as well as his previous action indicating the US government will move from promoting that people take vaccines to encouraging people to exercise informed consent in regard to vaccines, suggest a major shift in US policy is underway.
Since Friday, the price of Vaxart stock has been down about 30 percent. While this share price drop likely would have worried prior Health and Human Services secretaries who saw themselves as partners with the pharmaceutical industry, Kennedy seems to have other motivations that involve instead placing emphasis on priorities including advancing the health of Americans and ensuring his department has independence from special interests — including pharmaceutical companies.
